MA-PERKINELMER
20.4.2020 15:02:08 CEST | Business Wire | Press release
PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today expanded its analysis and automation portfolio for quality, safety and content testing. Geared for pharmaceutical, semiconductor, biomonitoring, food, materials and academia labs, the new offerings will help streamline workflows, sharpen insights and performance and provide ease of use. They include:
NexION® 5000 Multi-Quadruple ICP-MS – for demanding trace element analyses, this solution drives accurate and repeatable results and helps future-proof labs. Leveraging new and proprietary technologies, it is the first in its category to offer four quadrupoles – meeting and exceeding rigorous trace-elemental testing requirements for labs working in areas like semiconductor R&D and device manufacturing as well as biomonitoring. The new offering goes beyond current triple-quad ICP-MS performance to deliver exceptionally low background equivalent concentrations (BECs) of <1 ppt even in hot plasma and outstanding detection limits in a matrix-tolerant, low-maintenance solution.
Spectrum™ 3 spectrometer – a tri-range FT-IR spectroscopy solution featuring 100 scans/second for pharmaceutical, polymer, materials, food, academic or chemical labs doing advanced research, product development or reaction monitoring. Working across solid, liquid or gas samples and including options for near, mid and far-IR ranges in one instrument, it brings strong flexibility. It is also suitable for users of varying skill levels as it is the first FT-IR platform to offer a fully integrated TG-IR hyphenation (EGA4000) solution.
For more advanced applications, the offering can be easily hyphenated with PerkinElmer’s TGA™ 8000 thermogravimetric analyzer and Clarus® SQ8 GC/MS chromatography system. Spectrum 3 also leverages PerkinElmer’s Spectrum™ 10 software (including integrated time resolved software and CFR 21 Part 11 compliance options) and cloud connectivity via NetPlus™ software – delivering accurate results, integrated workflows and global, real-time collaboration.
Spectrum™ Two + spectrometer - a powerful FT-IR solution for routine compositional and quality analyses that delivers fast and accurate results with secure, cloud-connectivity. It also offers a compact footprint, advanced UATR (universal attenuated total reflectance) accessory and rugged touchscreen.
S20 Autosamplers Series - brings sample automation speed, ruggedness and versatility to labs looking to boost their productivity and cost savings, as well as future-proof their spectroscopy capabilities.
“Whether lab professionals are working to ensure the efficacy of pharmaceuticals, meeting materials regulations, aiming for zero impurities in semiconductor processes, or testing for food adulteration, they want to be more productive and collaborative and create highly reliable results and fresh insights,” said Suneet Chadha, VP/GM, Applied Markets, PerkinElmer. “Our new four quadrupole ICP-MS, FT-IR and automation solutions are designed to empower scientists and technicians to look deeper, work smarter and prepare for future needs or requirements.”
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise at www.perkinelmer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200420005047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
